Studies anxiety in men on prostate cancer active surveillance and partners
Observes anxiety in men with localized prostate cancer under monitoring and their partners.
Key facts
- Who runs it
- University Hospital, Lille
- Where
- Lille, FranceSee the site
- Trial code
- Registry title
- Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.
- Status
- Recruiting
- People taking part
- 432 people, planned
- Started
- 23 Mar 2025
- Expected to end
- 23 Mar 2027
- Type of study
- Observational
- Treatments tested
- Patient on active surveillance
- Record updated
- 20 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on active surveillance for localized prostate cancer at Lille University Hospital, who have a life partner. Partners take part too.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Localized prostate cancer, started active surveillance between 2007 and 2023
- Earlier treatment
- Must be on active surveillance and followed in the Urology Department of Lille University Hospital
Main reasons for not taking part
- Does not speak French well
- Minor, under legal protection, or deprived of liberty
- No medical insurance coverage
- Refuses to take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥ 18 years
- Patients who started active surveillance for localized prostate cancer from 2007 to 2023 and are followed in the Urology Department of Lille University Hospital
- Affiliation to a social security scheme
- Obtaining patient consent
- Having a life partner or an unidentified partner recognized as the person sharing the patient's daily life
Who cannot take part
- Lack of proficiency in the French language
- Minor patients, those under legal protection measures, or deprived of liberty
- Lack of medical insurance coverage
- Patients refusing to participate in the study
Where in France
- CHU de LilleLille, FranceContact: Jonathan OLIVIER, DrTaking people
About the trial
What the trial wants to find out
Prostate cancer (PCa) is the most common cancer and the third leading cause of cancer-related death among men in France.
Read full original descriptionShow less
Active surveillance is one of the management options for low-risk prostate cancer. Its aim is to delay or avoid radical treatment, such as surgery or radiotherapy, which can cause side effects including urinary incontinence, erectile dysfunction, or radiation-induced cystitis. Active surveillance involves regular monitoring of potential tumor progression through serum PSA testing, MRI scans, and prostate biopsies.
Few studies have investigated the psychological adjustment of patients undergoing active surveillance for prostate cancer, and even fewer have explored the relationship between the patients' anxiety symptoms and those of their partners. To our knowledge, no study has yet quantitatively or qualitatively assessed the anxiety of both patients and their partners. It appears essential to better characterize the anxiety symptoms in these individuals in order to offer them appropriate psychological support.
Treatments tested
- Patient on active surveillance
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Quantitative and Qualitative Study of Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.
- Plain-language title
- Studies anxiety in men on prostate cancer active surveillance and partnersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 January 2026